自从去年12月BMS终止了与Century Therapeutics的合作后,这家以开发诱导多能干细胞(iPSC)衍生疗法的细胞治疗公司似乎正在下坡路上一路狂奔。在今年第一季度CNTY-101变相宣布放弃竞争激烈的非霍奇金淋巴瘤,公司声称“临床数据没有达到该公司在该患者群体中被视为转化的阈值”,转向自免领域开发,癌症临床最后只在“显示受益的患者提供持续治疗”。而现在,公司宣布裁员51%,以实现公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.